Take the Diabetes Health Pump Survey
Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
Latest
Popular
Top Rated

Latest Medications Articles

Type 1 Glucose Production Pill on the Horizon
Two New Promising Type 2 Drugs in the Pipeline
What are your thoughts on insulin pumps?
Community’s Positive Effect on Diabetes Management
8th Q&A With Dr. Richard Bernstein
At the Crossroads, I Choose Insulin
Reduced Insulin May Prevent Exercise-Related Hypoglycemia
An Interview With My Husband, Rick
Living With Type 1 Diabetes
Smaller, Lighter OmniPod Earns FDA Approval
Diabetes Health Reference Charts
Mail Order Reference Guide (PDF)
Type 2 Meds Reference Guide (PDF)
Mail Order Reference Guide (PDF)
See All Charts…
Medications Archives
Browse the Medications Archives
Subscribe to the Medications RSS Feed
Print | Email | Share | Comments (0)

New Time-Released Brand of Metformin Well-Tolerated in Clinical Trials

Sep 1, 2000

Released at a Controlled Rate in Stomach

DepoMed of Menlo Park, California, reported a second set of positive phase I data for its oral anti-diabetic drug Metformin GR. Data from a five-day trial enrolling 14 healthy volunteers suggest that 1000 mg of Metformin GR once per day is as well-tolerated as two doses per day of 500 mg Glucophage.

Metformin GR, an extend-release product, is still in its development stage. It is designed to provide an alternative to Bristol-Myers Squibb's leading diabetes drug Glucophage, which requires twice-daily dosing.

Glucophage is scheduled to lose its patent this month.

Metformin GR is formulated using the company's Gastric Retention (GR) delivery technology. Using normal physiological processes where the stomach retains large objects for further digestion, the GR System swells following ingestion and is retained in the stomach for a number of hours. Once in the stomach, the drug is released at a controlled rate.

A larger phase II trial of Metformin GR is scheduled to begin in the third quarter.

Categories: Diabetes, Diabetes, Medications, Metformin, Type 2 Medications

Donate to Diabetes Health

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 0 comments - Sep 1, 2000

©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.